Rare Blood

Latest News

Hemophilia | Image credit: jarun011 - stock.adobe.com

Marstacimab Improved Key Bleeding Outcomes in Hemophilia A or B

June 26th 2025

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

hemophilia and kids | Image credit: Denira - stock.adobe.com

FDA Approves Jivi for Pediatric Patients Aged 7 to 12 Years With Hemophilia A

By Skylar Jeremias

May 19th 2025

FDA approval-Olivier Le Moal-stock.adobe.com

FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B

By Giuliana Grossi

March 28th 2025

Research Supports Need for Diversity in Hemophilia Trials and Reducing Resource Strain

By Giuliana Grossi

December 24th 2024

First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA

By Giuliana Grossi

December 23rd 2024

Treating PNH: Complement Inhibitors, Administration Modes, and Coordinated Care Needs

Join experts as they explore PNH pathophysiology, treatment strategies, clinical trials, and management challenges. Gain essential insights to enhance patient outcomes and optimize PNH treatment.

Visit Now

View the latest AJMC Peer Exchange on paroxysmal nocturnal hemoglobinuria (PNH)

More News

May 14th 2022

Montreal Cognitive Assessment May Hold Promise for Assessing Cognitive Impairment in SCD

Jaime Rosenberg

Among their sample cohort of 49 patients, the researchers found that scores on the Montreal Cognitive Assessment correlated with measures of both literacy and health literacy.

May 12th 2022

Adolescent, Young Adult Males With Sickle Cell Disease Lack Knowledge of Fertility Implications, Study Shows

Rose McNulty

Improved management of sickle cell disease has vastly improved life expectancy and reduced morbidity for affected patients, but the disease itself and its treatments carry fertility risks that many young patients and their caregivers are unaware of.

doctor with tablet as various symbols related to healthcare pass by

October 20th 2021

Cancer Treatments, Orphan Drugs, Gene Therapies Represent Big Areas to Watch in Specialty Drug Pipeline

Skylar Jeremias

During her presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting, Aimee Tharaldson, PhD, highlighted the most anticipated specialty pharmacy drugs awaiting FDA approval, including several treatments for cancer and rare diseases.

April 23rd 2021

Gene Transfer Therapy Requires Further Investigation Despite Potential Approval, Review Says

Larry Hanover

After a more than 35-year pursuit, the licensing of a gene therapy product for treating hemophilia may be available within 2 years.

...

3 4 5 6 7

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions